The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam

Anesthesia and Analgesia

Volumn 82, Issue 3, 1996, Pages 511-516

  Olkkola, Klaus T ^a   Ahonen, Jouni ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; MIDAZOLAM; PLACEBO; PYRROLE DERIVATIVE; HYPNOTIC SEDATIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SEDATION; VOLUNTEER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; METABOLIC CLEARANCE RATE; PSYCHOMOTOR PERFORMANCE;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; PLACEBOS; PSYCHOMOTOR PERFORMANCE;

EID: 0029664974     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199603000-00015     Document Type: Article

References (16)

1. Gonzales FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-52.
2. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989;46:521-7.
3. Wandel C, Böcker R, Böhrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73:658-61.
4. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Alfentanil disposition in vivo is mediated by CYP3A4 in humans [abstract]. Anesthesiology 1994;81:A380.
5. Gascon M-P, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
6. Hargreaves JA, Jezequel S, Houston JB. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam [abstract]. Br J Clin Pharmacol 1994;38:175P.
7. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
8. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafive on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6.
9. De Kroon IFI, Langendijk PNJ, De Goede PNFC. Simultaneous determination of midazolam and its three hydroxy metabolites in human plasma by electron-capture gas chromatography without derivatization. J Chromatogr 1989;491:107-16.
10. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 1990;532:203-6.
11. Inagaki K, Takagi J, Lor E, et al. Determination of fluconazole in human serum by solid-phase extraction and reversed-phase HPLC. Ther Drug Monit 1992;14:306-11.
12. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
13. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
14. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-9.
15. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51:1014-8.
16. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.